Serum asymmetric dimethylarginine levels in normotensive obese individuals

Medical Science Monitor

Volumn 16, Issue 11, 2010, Pages 536-539

  Koc, Fatih ^a   Tokac, Mehmet ^b   Erdem, Sami ^b   Kaya, Coskun ^b   Unlu, Ali ^b   Karabag, Turgut ^b   Vatankulu, Mehmet Akif ^b   Demir, Kenan ^b   Ayhan, Selim ^b   Kaya, Ahmet ^b  

^a GAZIOSMANPASA UNIVERSITY   (Turkey)

^b SELCUK UNIVERSITY   (Turkey)

Author keywords

Asymmetric dimethylarginine; Obesity

Indexed keywords

N(G),N(G) DIMETHYLARGININE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ARGININE; DRUG DERIVATIVE; ENZYME INHIBITOR; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD CHEMISTRY; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; OBESITY; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); GLUCOSE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR;

ADULT; ARGININE; BLOOD PRESSURE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; ENZYME INHIBITORS; HUMANS; MALE; MIDDLE AGED; OBESITY; RISK FACTORS;

EID: 79951566484     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Rogacev KS, Ulrich C, Blomer L et al: Monocyte heterogeneity in obesity and subclinical atherosclerosis. Eur Heart J, 2010; 31: 369-76.
2. Hamdy O, Ledbury S, Mullooly C et al: Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care, 2003; 26: 2119-25.
3. Chinali M, de Simone G, Roman MJ et al: Impact of obesity on cardiac geometry and function in a population of adolescents: the Strong Heart Study. J Am Coll Cardiol, 2006; 47: 2267-73.
4. Iacobellis G, Ribaudo MC, Zappaterreno A et al: Adapted changes in left ventricular structure and function in severe uncomplicated obesity. Obes Res, 2004; 12: 1616-21.
5. De Gennaro Colonna V, Bianchi M, Pascale V et al: Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule. Med Sci Monit, 2009; 15(4): RA91-101.
6. Boger RH, Bode-Boger SM, Szuba A et al: Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia. Circulation, 1998; 98: 1842-47.
7. Marliss EB, Chevalier S, Gougeon R et al: Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover. Diabetologia, 2006; 49: 351-59.
8. Cable DG, Celotto AC, Evora PR, Schaff HV: Asymmetric dimethylarginine endogenous inhibition of nitric oxide synthase causes differential vasculature effects. Med Sci Monit, 2009; 15(9): BR248-53.
9. Gruber HJ, Mayer C, Meinitzer A et al: Asymmetric dimethylarginine (ADMA) is tightly correlated with growth in juveniles without correlations to obesity related disorders. Exp Clin Endocrinol Diabetes, 2008; 116: 520-24.
10. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron, 1976; 16: 31-41.
11. Chen BM, Xia LW, Zhao RQ: Determination of N(G),N(G)- dimethylarginine in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl, 1997; 692: 467-71.
12. Sezgin AT, Sigirci A, Barutcu I et al: Vascular endothelial function in patients with slow coronary flow. Coron Artery Dis, 2003; 14: 155-61.
13. Eid HM, Arnesen H, Hjerkinn EM et al: Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metabolism, 2004; 53: 1574-79.
14. Vallance P, Leone A, Calver A et al: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet, 1992; 339: 572-75.
15. Sen N, Poyraz F, Tavil Y et al: Carotid intima-media thickness in patients with cardiac syndrome X and its association with high circulating levels of asymmetric dimethylarginine. Atherosclerosis, 2009; 204: 82-85.
16. Furuki K, Adachi H, Enomoto M et al: Plasma level of asymmetric dimethylarginine (ADMA) as a predictor of carotid intima-media thickness progression: six-year prospective study using carotid ultrasonography. Hypertens Res, 2008; 31: 1185-89.
17. Stuhlinger MC, Abbasi F, Chu JW et al: Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA, 2002; 287: 1420-26.
18. McLaughlin T, Stuhlinger M, Lamendola C et al: Plasma asymmetric dimethylarginine concentrations are elevated in obese insulin-resistant women and fall with weight loss. J Clin Endocrinol Metab, 2006; 91: 1896-900.
19. Romero-Corral A, Montori VM, Somers VK et al: Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet, 2006; 368: 666-78.
20. Smith SC Jr, Blair SN, Bonow RO et al: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic Cardiovascular Disease: 2001 update-a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol, 2001; 38: 1581-83.
21. Teplan V, Schuck O, Racek J et al: Asymmetric dimethylarginine in obesity after renal transplantation. J Ren Nutr, 2008; 18: 513-20.